Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06727552 · ClinicalTrials.gov registry record · Phase 2

A Study of Barzolvolimab in Patients With Atopic Dermatitis

A Phase 2 study of Atopic Dermatitis, sponsored by Celldex Therapeutics.

Active
Registry status
Phase 2
Development phase
131
Enrollment target
20
Study locations

NCT06727552 is a Phase 2 study of Atopic Dermatitis that is active but no longer recruiting, run by Celldex Therapeutics. The registered enrollment target is 131 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06727552, a Phase 2 study of Atopic Dermatitis, is active but no longer recruiting, sponsored by Celldex Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
131 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

Conditions Studied

Atopic Dermatitis

Interventions

  • DRUG Matching placebo
  • BIOLOGICAL Barzolvolimab

Study Locations (20)

California

  • Ohara Aivaz MD Dermatology - Beverly Hills
  • Advanced Dermatology Center - Burbank - Burbank
  • 310 Clinical Research - Inglewood
  • Avance Trials - Laguna Niguel
  • LA Universal Research Center, Inc. - Los Angeles
  • UCLA Division of Dermatology - Los Angeles
  • Dynasty Dermatology - Pasadena
  • Acclaim Clinical Research - San Diego
  • Clinical Science Institute - Santa Monica
  • FOMAT Medical Research - Allergy, Asthma, & Immunology Medical Group - Ventura
  • Pacific Clinical Innovations Inc. - Vista
  • Focus Clinical Research - West Hills

Florida

  • Direct Helpers Research Center - Hialeah
  • University of Miami - Miami
  • International Dermatology Research Inc - Miami - Miami Lakes
  • Sarasota Clinical Research - Sarasota
  • Well Pharma Medical Research Corporation - South Miami

Alabama

  • AllerVie Clinical Research - Birmingham
  • Cahaba Dermatology & Skin Health Center, LLC - Birmingham

Georgia

  • Centricity Research Columbus Dermatology - Columbus

Trial Details

FieldValue
Enrollment Target 131 participants
Start Date 2024-12-18
Est. Completion 2027-05
Phase Phase 2

Sponsor

Celldex Therapeutics

42 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06727552

The ClinicalTrials.gov registry entry for NCT06727552 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (78% lower). The listed sponsor is Celldex Therapeutics, which has 42 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Matching placebo is the first listed.

NCT06727552 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT06727552 about?

NCT06727552 is a clinical study titled "A Study of Barzolvolimab in Patients With Atopic Dermatitis". The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with Atopic Dermatitis

What is the current status of trial NCT06727552?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 131 participants. The study started on 2024-12-18. Estimated completion is 2027-05.

What conditions does trial NCT06727552 study?

This clinical trial studies the following conditions: Atopic Dermatitis.

What interventions are being tested in trial NCT06727552?

The interventions under investigation include: Matching placebo (DRUG), Barzolvolimab (BIOLOGICAL).

Who is sponsoring clinical trial NCT06727552?

This trial is sponsored by Celldex Therapeutics, which has 42 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06727552 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atopic Dermatitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atopic Dermatitis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.